PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30232145-5	2018	Pan-HDAC inhibitors, such as quisinostat, reversed the expression of a group of proteins that were deregulated in SCCOHT cells due to SMARCA4 loss, leading to growth arrest, apoptosis, and differentiation in vitro and suppressed tumor growth of xenografted tumors of SCCOHT cells.	quisinostat	29-40	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	134-141
29447615-4	2019	In this work, we explored the structural role of potassium ions in Site 1 and Site 2 and how they affect the interactions of compounds with high affinities for HDAC1 (AC1OCG0B, Chlamydocin, Dacinostat and Quisinostat) and SAHA (a pan-inhibitor) using molecular docking and molecular dynamics (MD) simulations in concert with a Molecular-Mechanics-Generalized-Born-Surface-Area (MMGBSA) approach.	quisinostat	205-216	histone deacetylase 1	Homo sapiens	160-165
30443188-10	2018	Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c- jun/caspase3 pathways.	quisinostat	16-27	H3 histone pseudogene 16	Homo sapiens	103-106
30443188-10	2018	Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c- jun/caspase3 pathways.	quisinostat	16-27	mitogen-activated protein kinase 8	Homo sapiens	120-123
30443188-3	2018	In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.	quisinostat	37-48	AKT serine/threonine kinase 1	Homo sapiens	147-150
30443188-3	2018	In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.	quisinostat	37-48	H3 histone pseudogene 16	Homo sapiens	151-154
30443188-10	2018	Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c- jun/caspase3 pathways.	quisinostat	16-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-130
30443188-3	2018	In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.	quisinostat	37-48	mitogen-activated protein kinase 8	Homo sapiens	180-183
30443188-10	2018	Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c- jun/caspase3 pathways.	quisinostat	16-27	caspase 3	Homo sapiens	131-139
30443188-3	2018	In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.	quisinostat	37-48	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	184-189
30443188-3	2018	In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.	quisinostat	37-48	caspase 3	Homo sapiens	190-198
28849080-0	2017	Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.	quisinostat	30-41	tumor protein p53	Homo sapiens	86-89
30443188-10	2018	Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c- jun/caspase3 pathways.	quisinostat	16-27	AKT serine/threonine kinase 1	Homo sapiens	99-102
29464063-2	2018	In this study we investigated as a potential novel therapeutic intervention for both cutaneous and uveal melanoma patients a combination of the broad spectrum HDAC inhibitor quisinostat and pan-CDK inhibitor flavopiridol.	quisinostat	174-185	histone deacetylase 9	Homo sapiens	159-163
28878027-7	2017	HDAC inhibitor pathway activation results in apoptosis and decreased tumor burden following a 7-day quisinostat treatment in the Ptenfl/fl;hSS2 mouse model of synovial sarcoma.	quisinostat	100-111	histone deacetylase 9	Homo sapiens	0-4
28878027-7	2017	HDAC inhibitor pathway activation results in apoptosis and decreased tumor burden following a 7-day quisinostat treatment in the Ptenfl/fl;hSS2 mouse model of synovial sarcoma.	quisinostat	100-111	butyrophilin like 2	Homo sapiens	139-143
28056055-5	2017	We find that the HDAC inhibitor quisinostat disrupts the SS18-SSX driving protein complex, thereby reestablishing expression of EGR1 and CDKN2A tumor suppressors.	quisinostat	32-43	SS18 subunit of BAF chromatin remodeling complex	Homo sapiens	57-61
28224725-4	2017	Quisinostat-treated SCNT embryos also possessed significantly increased AcH3K9 at the pseudo-pronuclear stage (p < 0.05), as well as improved immunostaining intensity for POU5F1 at the blastocyst stage (p < 0.05).	quisinostat	0-11	POU domain, class 5, transcription factor 1	Sus scrofa	174-180
28224725-5	2017	While no statistical difference in BAX expression was observed, BCL2 transcript abundance was significantly different in the quisinostat-treated compared to the untreated control group.	quisinostat	125-136	apoptosis regulator Bcl-2	Sus scrofa	64-68
28056055-5	2017	We find that the HDAC inhibitor quisinostat disrupts the SS18-SSX driving protein complex, thereby reestablishing expression of EGR1 and CDKN2A tumor suppressors.	quisinostat	32-43	early growth response 1	Homo sapiens	128-132
28056055-5	2017	We find that the HDAC inhibitor quisinostat disrupts the SS18-SSX driving protein complex, thereby reestablishing expression of EGR1 and CDKN2A tumor suppressors.	quisinostat	32-43	cyclin dependent kinase inhibitor 2A	Homo sapiens	137-143
28056055-7	2017	Quisinostat inhibits aggresome formation in response to proteasome inhibition, and combination treatment leads to elevated endoplasmic reticulum stress, activation of pro-apoptotic effector proteins BIM and BIK, phosphorylation of BCL-2, increased levels of reactive oxygen species, and suppression of tumor growth in a murine model of synovial sarcoma.	quisinostat	0-11	BCL2-like 11 (apoptosis facilitator)	Mus musculus	199-202
28056055-7	2017	Quisinostat inhibits aggresome formation in response to proteasome inhibition, and combination treatment leads to elevated endoplasmic reticulum stress, activation of pro-apoptotic effector proteins BIM and BIK, phosphorylation of BCL-2, increased levels of reactive oxygen species, and suppression of tumor growth in a murine model of synovial sarcoma.	quisinostat	0-11	B cell leukemia/lymphoma 2	Mus musculus	231-236
19682743-2	2010	JNJ-26481585 is a hydroxamic acid derivative, second-generation pan-HDAC inhibitor that has demonstrated high potency in preclinical studies.	quisinostat	0-12	histone deacetylase 9	Homo sapiens	68-72
27423454-5	2016	Up-acetylation of histones H3 and H4 and non-histone protein alpha-tubulin was induced by quisinostat treatment in a nanomolar concentration.	quisinostat	90-101	tubulin alpha 1b	Homo sapiens	61-74
27423454-8	2016	Bioinformatics analysis indicated that effects of quisinostat on NSCLC cells were associated with activated p53 signaling pathway.	quisinostat	50-61	tumor protein p53	Homo sapiens	108-111
27423454-9	2016	We found that quisinostat increased p53 acetylation at K382/K373 sites, upregulated the expression of p21(Waf1/Cip1), and resulted in G1 phase arrest.	quisinostat	14-25	tumor protein p53	Homo sapiens	36-39
27423454-9	2016	We found that quisinostat increased p53 acetylation at K382/K373 sites, upregulated the expression of p21(Waf1/Cip1), and resulted in G1 phase arrest.	quisinostat	14-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-105
27423454-9	2016	We found that quisinostat increased p53 acetylation at K382/K373 sites, upregulated the expression of p21(Waf1/Cip1), and resulted in G1 phase arrest.	quisinostat	14-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	106-110
27423454-9	2016	We found that quisinostat increased p53 acetylation at K382/K373 sites, upregulated the expression of p21(Waf1/Cip1), and resulted in G1 phase arrest.	quisinostat	14-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-115
26836950-2	2016	OBJECTIVES: To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).	quisinostat	56-67	TSPY like 2	Homo sapiens	131-135
26836950-15	2016	CONCLUSIONS: Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile.	quisinostat	13-24	TSPY like 2	Homo sapiens	117-121
19682743-5	2010	In conclusion, JNJ-26481585 is a potent second-generation pan-HDAC inhibitor with activity in human leukemia, and it is currently in clinical development.	quisinostat	15-27	histone deacetylase 9	Homo sapiens	62-66
19861438-0	2009	JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.	quisinostat	0-12	histone deacetylase 9	Homo sapiens	47-66
34004213-7	2021	In this study, we found that Qst suppressed RANKL-induced production of TRAP-positive mature osteoclasts, expression of osteoclast-specific genes, formation of F-actin rings, and bone resorption activity at a nanomolar concentration as low as 2 nM in vitro.	quisinostat	29-32	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	44-49
34004213-7	2021	In this study, we found that Qst suppressed RANKL-induced production of TRAP-positive mature osteoclasts, expression of osteoclast-specific genes, formation of F-actin rings, and bone resorption activity at a nanomolar concentration as low as 2 nM in vitro.	quisinostat	29-32	signal sequence receptor, delta	Mus musculus	72-76
30204052-6	2019	The free modeled structure of HDAC10 and its complexes with quisinostat and the highest-ranked compound ZINC19749069 were submitted to molecular dynamics simulation.	quisinostat	60-71	histone deacetylase 10	Homo sapiens	30-36
32363192-6	2020	Consistently, pharmaceutical inhibition with a small-molecule inhibitor of HDAC11 (quisinostat) attenuated unilateral ureteral obstruction (UUO) induced renal fibrosis in mice.	quisinostat	83-94	histone deacetylase 11	Mus musculus	75-81
32286289-7	2020	Our results identify H1.0 as a major mediator of Quisinostat"s antitumor effect and suggest that sequential administration of targeted therapy and Quisinostat may be a broadly applicable strategy to induce a prolonged response in patients.	quisinostat	49-60	H1.0 linker histone	Homo sapiens	21-25
30168013-5	2019	Furthermore, we comprehensively assessed the anti-ESCC activity of a highly active HDAC1 inhibitor quisinostat.	quisinostat	99-110	histone deacetylase 1	Homo sapiens	83-88